A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study)
- Conditions
- Gastric cancer
- Registration Number
- JPRN-UMIN000014789
- Lead Sponsor
- Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1) Multiple primary cancers with disease-free period less than 5-years, except carcinoma in situ or intra mucosal disease cured by local therapy 2) Past history of severe hypersensitivity to drug 3) Active incection 4) Fever more than 38 degree 5) Central nervous system metastasis or carcinomatous meningitis 6) Massive cardiac effusion, pleural effusion or ascites 7) Peripheral sensory neuropathy : grade 2 or above (CTCAE v4.0) 8) Chronic daily treatment with oral or intravenous corticosteroids 9) Unstable angina or past history of myocardinal infraction in 6 months 10) Evidence of any other serious disease ; renal failure, hepatic failure, interstinal pneumonitis or lung fibrosis 11) Pregnant, lactating female, female of childbearing potential or male without contracepcion intention 12) Psychiatric disease that is inapprocpriate for entry into this study 13) Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method